116
Participants
Start Date
January 11, 2024
Primary Completion Date
June 30, 2027
Study Completion Date
December 31, 2027
Disitamab Vedotin
2.0 mg/kg IV every 2 weeks
Zimberelimab
240mg IV every 2 weeks
NOT_YET_RECRUITING
Beijing Obstetrics and Gynecology Hospital ,Capital Medical University, Beijing
NOT_YET_RECRUITING
Liaoning Cancer Hospital & Institute, Shenyang
RECRUITING
Fudan University Shanghai Cancer Center, Shanghai
NOT_YET_RECRUITING
The first affiliated hospital of bengbu medical college, Bengbu
NOT_YET_RECRUITING
Shandong Cancer Hospital & Institute, Jinan
NOT_YET_RECRUITING
Tianjin Medical University Cancer Institute and Hospital, Tianjin
NOT_YET_RECRUITING
Zhejiang Cancer Hospital, Hangzhou
NOT_YET_RECRUITING
Jiangxi Maternal and Child Health Hospital, Nanchang
NOT_YET_RECRUITING
Chongqing University Cancer Hospital, Chongqing
NOT_YET_RECRUITING
Hunan Cancer Hospital, Changsha
NOT_YET_RECRUITING
Guangxi Tumor Hospital, Nanning
NOT_YET_RECRUITING
Yunnan Cancer Hospital, Kunming
RemeGen Co., Ltd.
INDUSTRY